1. Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022 Feb;21(2):125-139. Erratum in: Lancet Neurol. 2022 Jan 20; PMID: 35065036.
2. Kunz, D., Dauvilliers, Y., Benes, H. et al. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder. CNS Drugs. 37, 93–106 (2023). https://doi-org.libproxy1.nus.edu.sg/10.1007/s40263-022-00980-8